Loading video...

Video Failed to Load

There was a problem loading this video. This could be due to a temporary network issue or the video might be unavailable.

Chai Discovery's BioAI Phase Shift: Chai-3, Photoshop for Molecules, One-Shot Drug Design, & Engineering Biology Chai Discovery cofounder Matt McPartlon and product lead Neil Patil explain why AI drug design has crossed the threshold from impressive demos to pharma-trusted tools, how Chai-2 and Chai-3 are pushing toward one-shot therapeutic-grade... show more

Latent.Space

33,489 subscribers

22,037 views • 2 months ago •via X (Twitter)

Anya Rossi• Live Now

Private livecam show

2 Comments

晚晚2 months ago

@chaidiscovery @Mattmcpartlon1 @realdealpatil 分子版 Photoshop 很直观，one-shot 还得看湿实验成色。

Eggs inSpace2 months ago

@chaidiscovery @Mattmcpartlon1 @realdealpatil The shift from building pipelines to selling tools is the real signal. Pharma doesn't write cheques for promises, and four deals in a summer proves it.

Related Videos

Exclusive: Inside $3.8B Chai Discovery After leaving OpenAI & Stripe, co-founders Josh Meier (Joshua Meier) and Jack Dent (Jack Dent) built a pioneering AI drug design model called Chai-1. Now? Their models are used by giants like Eli Lilly, Pfizer and Novartis. Their models design antibodies in hours, not years - with atomic-level accuracy confirmed in the lab. If they're right, we're closer than ever to curing complex diseases. We went to San Francisco to find out. They've raised $600M + from sarah guo Lachy Groom Fred Ehrsam Thrive Capital Sequoia Capital General Catalyst OpenAI Menlo Ventures Index Ventures Kleiner Perkins + more. 0:00 AI drug design - how is it possible? 1:32 Josh: Leaving OpenAI for biology 2:34 90% of drugs used to fail 3:24 An outside scientist's honest take 4:40 Chai-3: Drug design in hours not years 5:30 Why Eli Lilly bet on Chai 6:20 When will this reach patients? 8:56 A hopeful future: Alzheimer's & aging

Exclusive: Inside $3.8B Chai Discovery After leaving OpenAI & Stripe, co-founders Josh Meier (Joshua Meier) and Jack Dent (Jack Dent) built a pioneering AI drug design model called Chai-1. Now? Their models are used by giants like Eli Lilly, Pfizer and Novartis. Their models design antibodies in hours, not years - with atomic-level accuracy confirmed in the lab. If they're right, we're closer than ever to curing complex diseases. We went to San Francisco to find out. They've raised $600M + from sarah guo Lachy Groom Fred Ehrsam Thrive Capital Sequoia Capital General Catalyst OpenAI Menlo Ventures Index Ventures Kleiner Perkins + more. 0:00 AI drug design - how is it possible? 1:32 Josh: Leaving OpenAI for biology 2:34 90% of drugs used to fail 3:24 An outside scientist's honest take 4:40 Chai-3: Drug design in hours not years 5:30 Why Eli Lilly bet on Chai 6:20 When will this reach patients? 8:56 A hopeful future: Alzheimer's & aging

Sachin and Adam

98,147 views • 3 months ago

To date, finding a drug has been a process of guess & check… screening millions of molecules hoping one binds. Chai Discovery is changing the paradigm… describe the molecule you want, and the model designs it. Joshua Meier and Matt McPartlon took antibody hit rates from roughly 1 in 1,000 to 1 in 7. That's the jump from search to engineering. On this episode of Training Data, they get into where the field actually is, why 2024 was the moment to start, what drug discovery looks like when the computer does the design, and more. 00:00 Introduction 01:52 From Discovery to Design 03:25 Protein AI Breakthroughs Timeline 06:04 Why Start in 2024 10:13 Diffusion Models Intuition 11:41 Building the Avengers Team 15:22 Hit Rates and Scaling Laws 25:01 Molecular CAD Vision 25:24 Faster Design Loops 26:32 Future Drug Discovery 28:37 Platform Business Model 31:14 Partnering Reality Check 33:44 Data Flywheel Explained 37:16 Staying Ahead at Scale 39:44 Culture and What's Next

To date, finding a drug has been a process of guess & check… screening millions of molecules hoping one binds. Chai Discovery is changing the paradigm… describe the molecule you want, and the model designs it. Joshua Meier and Matt McPartlon took antibody hit rates from roughly 1 in 1,000 to 1 in 7. That's the jump from search to engineering. On this episode of Training Data, they get into where the field actually is, why 2024 was the moment to start, what drug discovery looks like when the computer does the design, and more. 00:00 Introduction 01:52 From Discovery to Design 03:25 Protein AI Breakthroughs Timeline 06:04 Why Start in 2024 10:13 Diffusion Models Intuition 11:41 Building the Avengers Team 15:22 Hit Rates and Scaling Laws 25:01 Molecular CAD Vision 25:24 Faster Design Loops 26:32 Future Drug Discovery 28:37 Platform Business Model 31:14 Partnering Reality Check 33:44 Data Flywheel Explained 37:16 Staying Ahead at Scale 39:44 Culture and What's Next

Pat Grady

35,618 views • 2 months ago

"We have this long term vision of turning biology from something which is trial and error and experimental and make it something that looks more like an engineering discipline in the next century." New Episode with Jack Dent ! 0:00 Intro 02:28 Inside Stripe w/ Patrick Collison, at <100 People 08:45 Sam Altman role in Chai Discovery origin 16:20 Chai-2 Antibody Breakthrough 19:24 Approaching biology as an engineering problem 24:45 Using AI models to treat people on an individual scale 26:52 Robotics in labs 27:22 Pharma industry today 29:49 The clinical trial bottleneck 32:53 Personalized biology models & cancer vaccines 36:24 Longevity, peptides, and trillion-dollar drugs 39:02 Does it matter that the government cut exploratory science grants? 41:00 What next-gen Chai models will do 42:08 Can frontier AI labs build this themselves? 43:26 Biology is hard

"We have this long term vision of turning biology from something which is trial and error and experimental and make it something that looks more like an engineering discipline in the next century." New Episode with Jack Dent ! 0:00 Intro 02:28 Inside Stripe w/ Patrick Collison, at <100 People 08:45 Sam Altman role in Chai Discovery origin 16:20 Chai-2 Antibody Breakthrough 19:24 Approaching biology as an engineering problem 24:45 Using AI models to treat people on an individual scale 26:52 Robotics in labs 27:22 Pharma industry today 29:49 The clinical trial bottleneck 32:53 Personalized biology models & cancer vaccines 36:24 Longevity, peptides, and trillion-dollar drugs 39:02 Does it matter that the government cut exploratory science grants? 41:00 What next-gen Chai models will do 42:08 Can frontier AI labs build this themselves? 43:26 Biology is hard

Sabrina Halper

39,998 views • 5 months ago

We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇

We’re excited to introduce Chai-2, a major breakthrough in molecular design. Chai-2 enables zero-shot antibody discovery in a 24-well plate, exceeding previous SOTA by >100x. Thread👇

Chai Discovery

714,505 views • 1 year ago

Congratulations Chai Discovery - entering a golden age of biology

Congratulations Chai Discovery - entering a golden age of biology

Sabrina Halper

22,222 views • 3 months ago

David Baker’s next bet is bigger than protein design. UW, the Allen Institute, and Fred Hutch just launched AI BioDesign with $95M in funding — an open-science effort to build a continuous design-build-measure-learn loop for biology. The goal is not just to predict what nature has made, but to explore what biology could make next. From proteins and regulatory elements to cells and entirely new biological functions, this feels like a shift from “AI for understanding biology” to “AI for engineering biology.”

David Baker’s next bet is bigger than protein design. UW, the Allen Institute, and Fred Hutch just launched AI BioDesign with $95M in funding — an open-science effort to build a continuous design-build-measure-learn loop for biology. The goal is not just to predict what nature has made, but to explore what biology could make next. From proteins and regulatory elements to cells and entirely new biological functions, this feels like a shift from “AI for understanding biology” to “AI for engineering biology.”

BioTender

26,319 views • 1 month ago

Chai Discovery cofounder Jack Dent says AI drug discovery hit a major inflection point in 2025. As a result, it's now being deployed at the biggest pharma companies as part of their core discovery engines. "Over the course of 2025, these models went from being research curiosities... to being able to design molecules without needing to fine-tune them on a lot of data." "You can really just prompt them in the way that you'd prompt an LLM with a target, maybe some disease you're going after. And they will design a number of candidates that would help do that, essentially." "A year, year and a half ago, basically none of this stuff worked." "In 2025 we really crossed the Rubicon. And now these technologies are actively being deployed in companies like Eli Lilly, Novartis, Pfizer. These are some of the most scientific, highest-tech companies in the world. And they're putting them into real drug programs and making them part of their core discovery engines."

Chai Discovery cofounder Jack Dent says AI drug discovery hit a major inflection point in 2025. As a result, it's now being deployed at the biggest pharma companies as part of their core discovery engines. "Over the course of 2025, these models went from being research curiosities... to being able to design molecules without needing to fine-tune them on a lot of data." "You can really just prompt them in the way that you'd prompt an LLM with a target, maybe some disease you're going after. And they will design a number of candidates that would help do that, essentially." "A year, year and a half ago, basically none of this stuff worked." "In 2025 we really crossed the Rubicon. And now these technologies are actively being deployed in companies like Eli Lilly, Novartis, Pfizer. These are some of the most scientific, highest-tech companies in the world. And they're putting them into real drug programs and making them part of their core discovery engines."

TBPN

29,503 views • 3 months ago

FULL EXPLANATION: Works In Progress' Ruxandra Teslo 🧬 on Anthropic's Protein Binding, Drug Design, The Methodology, RF Diffusion, Alpha Fold, Generative AI & Biology, Curing All Diseases in 10 Years, Mini Research Assistants, Automating Science: 2:00 - How To Design A Drug 3:30 - Bottle Neck's To Molecule Design 5:07 - David Baker's RF Diffusion 6:08 - Claude Science 8:06 - How Significant Is This? 11:29 - Automating Drug Discovery 13:10 - Biology Communities Response 14:12 - Comms Strategy

FULL EXPLANATION: Works In Progress' Ruxandra Teslo 🧬 on Anthropic's Protein Binding, Drug Design, The Methodology, RF Diffusion, Alpha Fold, Generative AI & Biology, Curing All Diseases in 10 Years, Mini Research Assistants, Automating Science: 2:00 - How To Design A Drug 3:30 - Bottle Neck's To Molecule Design 5:07 - David Baker's RF Diffusion 6:08 - Claude Science 8:06 - How Significant Is This? 11:29 - Automating Drug Discovery 13:10 - Biology Communities Response 14:12 - Comms Strategy

etn.

18,514 views • 2 months ago

"Our integrated system narrows millions of molecules down to a short list that's synthetically accessible. Not just promising in silico, but actually makeable before a single one is sent to the labs." Traditional drug design often leans on decades of precedent and familiar chemistry. In Part 6 of our platform series, SVP of Drug Design Donovan Chin, Ph.D., explains how Recursion breaks that mold by getting a full computational design cycle up and running in about a day. Our AI-native engine vastly increases the aperture for our chemists. Instead of relying solely on known binding pockets, they can efficiently explore entirely novel and complex chemical space. By leveraging our integrated data, the team can forecast non-obvious design hypotheses and predict how to synthesize molecules even when nothing like them currently exists. This process begins by scoring binding affinity using advanced 3D structural models like Nesso-1. From there, the team runs hundreds of integrated models covering ADME, potency, advanced simulations, and AI retrosynthesis. This unified system rapidly filters millions of potential molecules down to a precise shortlist of high-quality candidates that are physically ready for the lab. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #ComputationalChemistry #DrugDiscovery #MachineLearning

"Our integrated system narrows millions of molecules down to a short list that's synthetically accessible. Not just promising in silico, but actually makeable before a single one is sent to the labs." Traditional drug design often leans on decades of precedent and familiar chemistry. In Part 6 of our platform series, SVP of Drug Design Donovan Chin, Ph.D., explains how Recursion breaks that mold by getting a full computational design cycle up and running in about a day. Our AI-native engine vastly increases the aperture for our chemists. Instead of relying solely on known binding pockets, they can efficiently explore entirely novel and complex chemical space. By leveraging our integrated data, the team can forecast non-obvious design hypotheses and predict how to synthesize molecules even when nothing like them currently exists. This process begins by scoring binding affinity using advanced 3D structural models like Nesso-1. From there, the team runs hundreds of integrated models covering ADME, potency, advanced simulations, and AI retrosynthesis. This unified system rapidly filters millions of potential molecules down to a precise shortlist of high-quality candidates that are physically ready for the lab. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #ComputationalChemistry #DrugDiscovery #MachineLearning

Recursion

1,091,624 views • 19 days ago

Check how FD block illegal footpath encroachment has been removed. Saying he used to come at night for adda and chai, now unable to get chai.

Check how FD block illegal footpath encroachment has been removed. Saying he used to come at night for adda and chai, now unable to get chai.

The Bong Head

17,252 views • 4 months ago

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from CMC Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation:

🚀 Reshaping drug discovery – and the future of medicine – with AI. Recursion CFO Ben Taylor joined the Opto Sessions podcast from CMC Aureon to share how Recursion uses AI, lab automation, biological data, and machine learning to improve the way new medicines are discovered and developed. 💠 They discuss: ▪️How pairing AI with lab automation across biology, chemistry, and clinical technology allows us to move beyond the ~10–12% of the genome currently addressed by approved or in-trial medicines and explore the vast realm of untapped biology. ▪️How Recursion is advancing REC-4881 for patients with familial adenomatous polyposis (FAP) — a progressive condition with no approved medical therapies — after achieving Phase 2 proof-of-concept and demonstrating meaningful reductions in polyp burden. ▪️How Recursion is compressing timelines and improving efficiency with high-quality, ML-ready data to design better molecules with ~90% fewer experimental chemistries and to run smarter, faster clinical trials. 👉 Check out the full conversation:

Recursion

98,892 views • 3 months ago

To go deeper on our new Life Sciences model series, research lead Joy Jiao and product lead Yunyun Wang joined Andrew Mayne on the OpenAI Podcast to discuss how we’re building models for biology, drug discovery, and translational medicine. They cover both the opportunity and the responsibility ahead: better research workflows today, more autonomous labs over time, and careful deployment from day one.

To go deeper on our new Life Sciences model series, research lead Joy Jiao and product lead Yunyun Wang joined Andrew Mayne on the OpenAI Podcast to discuss how we’re building models for biology, drug discovery, and translational medicine. They cover both the opportunity and the responsibility ahead: better research workflows today, more autonomous labs over time, and careful deployment from day one.

OpenAI

438,721 views • 6 months ago

Cool product for chai lovers. I always end up babysitting chai on the stove to stop it from boiling over, and half the time I still make a mess. The Loka solves that in a clever way and makes great chai. $150, but it is a really nice product

Cool product for chai lovers. I always end up babysitting chai on the stove to stop it from boiling over, and half the time I still make a mess. The Loka solves that in a clever way and makes great chai. $150, but it is a really nice product

Sheel Mohnot

137,983 views • 8 months ago

How could #AlphaFold 3 transform drug discovery? Most drugs are small molecules known as ligands that bind to proteins to change how they interact in human health and disease. AlphaFold 3 can predict these interactions to atomic accuracy.

How could #AlphaFold 3 transform drug discovery? Most drugs are small molecules known as ligands that bind to proteins to change how they interact in human health and disease. AlphaFold 3 can predict these interactions to atomic accuracy.

Isomorphic Labs

75,442 views • 2 years ago

$"Across our programs, we've advanced quality novel candidates after synthesizing only around 300 compounds, roughly 90% fewer than the industry average." Now that we have mapped the biology, we need to design the exact molecule to target it. In Part 5 of our platform series, SVP of Drug Design Donovan Chin, Ph.D., and VP of Pharmacology Martin Redhead, Ph.D., break down how we transition from biological target discovery to navigating complex chemical space. Just like our approach to biology, we solve chemistry problems through a continuous feedback loop between computation and experimentation. Before a single molecule is ever synthesized in the lab, our team uses Centaur, our integrated drug design environment. By combining hundreds of machine learning and physics-based models into a single platform, we can iteratively design novel molecular structures starting directly from target properties. This generative de novo design approach automatically updates our models so they improve with every single cycle. Our AI-native product engine has already produced over 10 development candidates. By holding our chemistry to the same rigorous standards as our biology, we can synthesize a fraction of the traditional compound volume while delivering superior novel molecules. We believe this focus on quality and novelty over sheer volume will define the true impact of AI on drug development. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #AIDrugDiscovery #DrugDiscovery #Chemistry$

"Across our programs, we've advanced quality novel candidates after synthesizing only around 300 compounds, roughly 90% fewer than the industry average." Now that we have mapped the biology, we need to design the exact molecule to target it. In Part 5 of our platform series, SVP of Drug Design Donovan Chin, Ph.D., and VP of Pharmacology Martin Redhead, Ph.D., break down how we transition from biological target discovery to navigating complex chemical space. Just like our approach to biology, we solve chemistry problems through a continuous feedback loop between computation and experimentation. Before a single molecule is ever synthesized in the lab, our team uses Centaur, our integrated drug design environment. By combining hundreds of machine learning and physics-based models into a single platform, we can iteratively design novel molecular structures starting directly from target properties. This generative de novo design approach automatically updates our models so they improve with every single cycle. Our AI-native product engine has already produced over 10 development candidates. By holding our chemistry to the same rigorous standards as our biology, we can synthesize a fraction of the traditional compound volume while delivering superior novel molecules. We believe this focus on quality and novelty over sheer volume will define the true impact of AI on drug development. 🚀 Follow along over the coming weeks as we continue this series, covering how Recursion maps biology, optimizes precision drug design, and closes the gap between patient and discovery. #TechBio #DrugDesign #AIDrugDiscovery #DrugDiscovery #Chemistry

Recursion

1,018,386 views • 22 days ago

How Mark Zuckerberg Will Defeat Aging Mark Zuckerberg is betting on virtual cell models. The shift is radical. Not biologists using AI, but AI that truly understands biology and leads discovery. Risky ideas move from slow, expensive wet labs to fast, cheap simulations. That’s how stopping aging stops being science fiction and starts becoming an engineering problem.

How Mark Zuckerberg Will Defeat Aging Mark Zuckerberg is betting on virtual cell models. The shift is radical. Not biologists using AI, but AI that truly understands biology and leads discovery. Risky ideas move from slow, expensive wet labs to fast, cheap simulations. That’s how stopping aging stops being science fiction and starts becoming an engineering problem.

VraserX e/acc

36,479 views • 8 months ago

My talk from the AI Engineer Code Summit is out! 🚨 "How Claude Code Works" and what we can learn about frontier agent architectures. Coding agents are suddenly really really good, and I'm trying to understand why. In short: better models, simple loop design, and bash tools

My talk from the AI Engineer Code Summit is out! 🚨 "How Claude Code Works" and what we can learn about frontier agent architectures. Coding agents are suddenly really really good, and I'm trying to understand why. In short: better models, simple loop design, and bash tools

Jared Zoneraich

13,936 views • 10 months ago

The British hooked an entire new market on to Chai...us Indians! Free chai at railway stations, tea breaks at factories, and once we got hooked they started charging us for it. Part 3 of 3

The British hooked an entire new market on to Chai...us Indians! Free chai at railway stations, tea breaks at factories, and once we got hooked they started charging us for it. Part 3 of 3

Amish Tripathi | Author | Broadcasting | History

10,769 views • 4 months ago